Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art of angiogenesis and therapy with a compendium of scientific findings and approaches to the study of angiogenesis in cancer. Leaders in the field present chapters on such topics as the environmental influences and the genetic and physiologic abnormalities that mediate angiogenesis and its role in the progression of malignant disease, working models of tumor angiogenesis, and the role of angiogenesis inhibition in the therapy of malignant disease in humans.
Comprehensive and cutting-edge, Antiangiogenic Agents in Cancer Therapy, Second Edition is an ideal, valuable guide to the most recent advances in the field, and a collection that will be useful for many years to come.
Antiangiogenesis, 2nd edition Table of Contents Beverly A. Teicher and Lee M. Ellis, editors 1. The vascular endothelial growth factor family and its receptors. Daniel J. Hicklin 2. The cycle between angiogenesis, perfusion and hypoxia in tumors. Mark W. Dewhirst, Yiting Cao, Gordana Vlahovic 3. The role of integrins in tumor angiogenesis. Aparna R. Aiyer, Judith A. Varner 4. Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Adam P. Dicker 5. Tumor endothelial cell abnormalities. Andrew C. Dudley, Michael Klagsbrun 6. The extracellular matrix and VEGF processing. Sunyoung Lee, M. Luisa Iruela-Arispe 7. Endothelial precursor cells. Rebecca G. Bagley 8. Role of pericytes in angiogenesis. Chunhua Lu, Anil K. Sood 9. VEGF in the adult: Implications for anti-VEGF therapies.Arindel S. R. Maharaj, Patricia D’Amore 10. Newer Vascular Targets. Beverly A. Teicher 11. Chemokines in Angiogenesis. Michael P. Keane, John A. Belperio, Robert M. Strieter 12. Angiopoietins and Tie receptors. Hanako Kobayashi, Laura M. DeBusk, P. Charles Lin 13. Imaging angiogenesis. Sanjeev P. Kalva, Saravanan Namasivayam, Dushyant Vasuedeo Sahani 14. VEGF and Tumor Vascular Structure. Yineng Fu, Ann M. Dvorak, Harold F. Dvorak 15. Lymphatic system in the pathology of cancer. Bronek Pytowski 16. Metronomic lo dose antiangiogenic chemotherapy in mice and man. Robert S. Kerbel, UEmmenegger, S Man, R Munoz, C Folkins, Y Shaked 17. Small molecule vascular disrupting agents in cancer therapy. Dietmar W. Siemann, Michael R. Horsman 18. Challenges in translating anti-angiogenic therapy from the bench to bedside. Lee M. Ellis, Nikolaos A. Dallas, George van Buren II, Sherry Lim, Ling Xia, Fan Fan, Michael J. Gray 19. Prognostic and predictive significance of surrogate biomarkers of angiogenesis. Raffaelo Longo, Francesco Torino, Giampietro Gasparini 20. Regulation of angiogenesis in cancer and its therapeutic implications. Liangfeng Han, Annaka M. Lorincz, Saraswati Sukumar 21. Angiogenesis and Angiogenesis inhibition in Sarcomas. Steven DuBois, George Demetri 22. Anti-angiogenesis agents in colorectal cancer. Axel Grothey 23. Antiangiogenic therapy for primary CNS tumors. Katherine E. Warren, Howard A. Fine 24. Angiogenesis inhibitors for the treatment of small cell and non-small cell lung cancer. Monique B. Nilsson, Emer O. Hanrahan, John V. Heymach 25. Anti-angiogenic therapy of renal carcinoma. Michael S. Gordon, Scot W. Ebbinghaus 26. Antiangiogenesis Therapies in Gynecological Malignancies. Robert A. Burger 27. Anti-angiogenic agents in myeloid malignancies. Magda Melchert, Alan F. List 28. Angiogenesis in malignant and non-malignant pediatric tumors. Domenico Ribatti, Mirco Ponzoni 29. Endpoints for the determination of efficacy of antiangiogenic agents in clinical trials. Joseph Paul Eder, Dan S. Zuckerman 30. The role of imaging